Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, shares insights into the current research on CAR-T therapy to treat multiple myeloma, and how it compares to monoclonal antibody treatment and stem cell transplantation (SCT). Prof. Nagler highlights that despite promising initial results, further studies are required to prove the safety and efficacy of CAR-T therapy. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.